Prophylactic Antibiotic Choice and Deep Infection in Lower Extremity Endoprosthetic Reconstruction: Comparison of Cefazolin, Cefazolin-Vancomycin, and Alternative Regimens.

IF 2.6 2区 医学 Q1 ORTHOPEDICS
Katherine S Hajdu, Stephen W Chenard, Anthony D Judice, Julia C Quirion, Aleksander P Mika, William B Gilbert, William Hefley, Daniel J Johnson, Patty W Wright, Hakmook Kang, Jennifer L Halpern, Herbert S Schwartz, Ginger E Holt, Joshua M Lawrenz
{"title":"Prophylactic Antibiotic Choice and Deep Infection in Lower Extremity Endoprosthetic Reconstruction: Comparison of Cefazolin, Cefazolin-Vancomycin, and Alternative Regimens.","authors":"Katherine S Hajdu, Stephen W Chenard, Anthony D Judice, Julia C Quirion, Aleksander P Mika, William B Gilbert, William Hefley, Daniel J Johnson, Patty W Wright, Hakmook Kang, Jennifer L Halpern, Herbert S Schwartz, Ginger E Holt, Joshua M Lawrenz","doi":"10.5435/JAAOS-D-24-00211","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Infection is a common mode of failure in lower extremity endoprostheses. The Prophylactic Antibiotic Regimens in Tumor Surgery trial reported that 5 days of cefazolin had no difference in surgical site infection compared with 24 hours of cefazolin. Our purpose was to evaluate infection rates of patients receiving perioperative cefazolin monotherapy, cefazolin-vancomycin dual therapy, or alternative antibiotic regimens.</p><p><strong>Methods: </strong>A single-center retrospective review was conducted on patients who received lower extremity endoprostheses from 2008 to 2021 with minimum 1-year follow-up. Three prophylactic antibiotic regimen groups were compared: cefazolin monotherapy, cefazolin-vancomycin dual therapy, and alternative regimens. The primary outcome was deep infection, defined by a sinus tract, positive culture, or clinical diagnosis. Secondary outcomes were revision surgery, microorganisms isolated, and superficial wound issues.</p><p><strong>Results: </strong>The overall deep infection rate was 10% (30/294) at the median final follow-up of 3.0 years (IQR 1.7 to 5.4). The deep infection rates in the cefazolin, cefazolin-vancomycin, and alternative regimen groups were 8% (6/72), 10% (18/179), and 14% (6/43), respectively ( P = 0.625). Patients not receiving cefazolin had an 18% deep infection rate (6/34) and 21% revision surgery rate (7/34) compared with a 9% deep infection rate (24/260) ( P = 0.13) and 12% revision surgery rate (31/260) ( P = 0.17) in patients receiving cefazolin. In those not receiving cefazolin, 88% (30/34) were due to a documented penicillin allergy, only two being anaphylaxis. All six patients in the alternative regimen group who developed deep infections did not receive cefazolin secondary to nonanaphylactic penicillin allergy.</p><p><strong>Conclusion: </strong>The addition of perioperative vancomycin to cefazolin in lower extremity endoprosthetic reconstructions was not associated with a lower deep infection rate. Patients who did not receive cefazolin trended toward higher rates of deep infection and revision surgery, although not statistically significant. The most common reason for not receiving cefazolin was a nonanaphylactic penicillin allergy, highlighting the continued practice of foregoing cefazolin unnecessarily.</p>","PeriodicalId":51098,"journal":{"name":"Journal of the American Academy of Orthopaedic Surgeons","volume":" ","pages":"e1166-e1175"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Orthopaedic Surgeons","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5435/JAAOS-D-24-00211","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Infection is a common mode of failure in lower extremity endoprostheses. The Prophylactic Antibiotic Regimens in Tumor Surgery trial reported that 5 days of cefazolin had no difference in surgical site infection compared with 24 hours of cefazolin. Our purpose was to evaluate infection rates of patients receiving perioperative cefazolin monotherapy, cefazolin-vancomycin dual therapy, or alternative antibiotic regimens.

Methods: A single-center retrospective review was conducted on patients who received lower extremity endoprostheses from 2008 to 2021 with minimum 1-year follow-up. Three prophylactic antibiotic regimen groups were compared: cefazolin monotherapy, cefazolin-vancomycin dual therapy, and alternative regimens. The primary outcome was deep infection, defined by a sinus tract, positive culture, or clinical diagnosis. Secondary outcomes were revision surgery, microorganisms isolated, and superficial wound issues.

Results: The overall deep infection rate was 10% (30/294) at the median final follow-up of 3.0 years (IQR 1.7 to 5.4). The deep infection rates in the cefazolin, cefazolin-vancomycin, and alternative regimen groups were 8% (6/72), 10% (18/179), and 14% (6/43), respectively ( P = 0.625). Patients not receiving cefazolin had an 18% deep infection rate (6/34) and 21% revision surgery rate (7/34) compared with a 9% deep infection rate (24/260) ( P = 0.13) and 12% revision surgery rate (31/260) ( P = 0.17) in patients receiving cefazolin. In those not receiving cefazolin, 88% (30/34) were due to a documented penicillin allergy, only two being anaphylaxis. All six patients in the alternative regimen group who developed deep infections did not receive cefazolin secondary to nonanaphylactic penicillin allergy.

Conclusion: The addition of perioperative vancomycin to cefazolin in lower extremity endoprosthetic reconstructions was not associated with a lower deep infection rate. Patients who did not receive cefazolin trended toward higher rates of deep infection and revision surgery, although not statistically significant. The most common reason for not receiving cefazolin was a nonanaphylactic penicillin allergy, highlighting the continued practice of foregoing cefazolin unnecessarily.

下肢假体重建中预防性抗生素的选择与深部感染:头孢唑啉、头孢唑啉-万古霉素和替代方案的比较。
导言:感染是下肢内固定失败的常见原因。肿瘤手术中的预防性抗生素方案试验报告显示,与 24 小时使用头孢唑啉相比,5 天使用头孢唑啉对手术部位感染的影响没有差异。我们的目的是评估围手术期接受头孢唑啉单药治疗、头孢唑啉-万古霉素双药治疗或其他抗生素方案的患者的感染率:方法: 对2008年至2021年期间接受下肢内固定术且随访至少1年的患者进行了单中心回顾性研究。比较了三组预防性抗生素方案:头孢唑啉单药治疗、头孢唑啉-万古霉素双药治疗和替代方案。主要结果是深部感染,定义为窦道、培养阳性或临床诊断。次要结果是翻修手术、分离出的微生物和表皮伤口问题:在中位 3.0 年(IQR 1.7 至 5.4)的最终随访中,总体深度感染率为 10%(30/294)。头孢唑啉组、头孢唑啉-万古霉素组和替代方案组的深度感染率分别为 8%(6/72)、10%(18/179)和 14%(6/43)(P = 0.625)。未接受头孢唑啉治疗的患者深部感染率为 18%(6/34),翻修手术率为 21%(7/34),而接受头孢唑啉治疗的患者深部感染率为 9%(24/260)(P = 0.13),翻修手术率为 12%(31/260)(P = 0.17)。在未接受头孢唑啉治疗的患者中,88%(30/34)是由于有记录的青霉素过敏,只有两人是过敏性休克。替代方案组中出现深度感染的六名患者均因非过敏性青霉素过敏而未接受头孢唑啉治疗:结论:在下肢假体置换术中,围手术期在头孢唑啉基础上加用万古霉素并不会降低深度感染率。未接受头孢唑啉治疗的患者深部感染率和翻修手术率呈上升趋势,但无统计学意义。未接受头孢唑啉治疗的最常见原因是非过敏性青霉素过敏,这说明仍存在不必要地放弃头孢唑啉治疗的做法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
6.20%
发文量
529
审稿时长
4-8 weeks
期刊介绍: The Journal of the American Academy of Orthopaedic Surgeons was established in the fall of 1993 by the Academy in response to its membership’s demand for a clinical review journal. Two issues were published the first year, followed by six issues yearly from 1994 through 2004. In September 2005, JAAOS began publishing monthly issues. Each issue includes richly illustrated peer-reviewed articles focused on clinical diagnosis and management. Special features in each issue provide commentary on developments in pharmacotherapeutics, materials and techniques, and computer applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信